Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Results from the ACE‐536‐MF‐001 study

Francesco Passamonti • 7 Sep 2023
SOHO 2023
Myelofibrosis Myeloproliferative Neoplasms Luspatercept Ruxolitinib
ACE‐536‐MF‐001

In this video, Francesco Passamonti, MD, University of Insubria, Varese, Italy, shares some results from the Phase II ACE‐536‐MF‐001 study (NCT03194542). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesco Passamonti

1:19
The current state-of-the-art in PV and future outlooks
Francesco Passamonti • 7 Sep 2023
1:00
Current and emerging treatment options for anemia in MF
Francesco Passamonti • 7 Sep 2023
1:14
Modern prognostication in MPNs: improving risk stratification & treatment approaches
Francesco Passamonti • 7 Sep 2023
1:30
Optimal approach to first-line therapy in myelofibrosis
Francesco Passamonti • 11 Jun 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals